Targeting ALK in Cancer: Therapeutic Potential of Proapoptotic Peptides
AbstractALK is a receptor tyrosine kinase, associated with many tumor types as diverse as anaplastic large cell lymphomas, inflammatory myofibroblastic tumors, breast and renal cell carcinomas, non-small cell lung cancer, neuroblastomas, and more. This makes ALK an attractive target for cancer therapy. Since ALK–driven tumors are dependent for their proliferation on the constitutively activated ALK kinase, a number of tyrosine kinase inhibitors have been developed to block tumor growth. While some inhibitors are under investigation in clinical trials, others are now approved for treatment, notably in ALK-positive lung cancer. Their efficacy is remarkable, however limited in time, as the tumors escape and become resistant to the treatment through different mechanisms. Hence, there is a pressing need to target ALK-dependent tumors by other therapeutic strategies, and possibly use them in combination with kinase inhibitors. In this review we will focus on the therapeutic potential of proapoptotic ALK-derived peptides based on the dependence receptor properties of ALK. We will also try to make a non-exhaustive list of several alternative treatments targeting ALK-dependent and independent signaling pathways. View Full-Text
Share & Cite This Article
Aubry, A.; Galiacy, S.; Allouche, M. Targeting ALK in Cancer: Therapeutic Potential of Proapoptotic Peptides. Cancers 2019, 11, 275.
Aubry A, Galiacy S, Allouche M. Targeting ALK in Cancer: Therapeutic Potential of Proapoptotic Peptides. Cancers. 2019; 11(3):275.Chicago/Turabian Style
Aubry, Arthur; Galiacy, Stéphane; Allouche, Michèle. 2019. "Targeting ALK in Cancer: Therapeutic Potential of Proapoptotic Peptides." Cancers 11, no. 3: 275.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.